Diabetes Care: Is the prognosis worse for young people with diabetes?

With the increasing prevalence of overweight and obesity, type 2 diabetes (T2DM) is becoming more and more common in young people and adults

In the Adolescent Type 2 Diabetes Treatment Program (TODAY) study, adolescents with T2DM were monitored for an average of 3.

It is worth noting that the β-cell function and blood glucose control of young adults in TODAY deteriorated faster than previously reported in adults ; however, no previous study directly compared T2DM in young adults and adults longitudinally in the same study

To this end, experts from the University of Chicago, the University of Washington, and several other universities have jointly launched a "preserving insulin secretion capacity (RISE) study" to evaluate whether drug intervention can successfully restore or protect patients with glucose.

A total of 91 adolescents (10-19 years old) were randomly assigned 1:1 to the 12-month metformin (MET) group or 3-month glenin + 9-month metformin group (G-MET), and 267 adults in the study People were randomly assigned to MET, G-MET, liraglutide plus MET (LIRA+MET) or placebo for 12 months

The change in blood glucose from baseline in M12 (under treatment) and M21 (9 months after discontinuation)

The results showed that at the 12th month, 17.

In both age groups, a lower baseline β-cell response predicted worsening of blood glucose at the 12th and 21st months (P<0.

Life table estimation from IGT to type 2 diabetes

Compared with adults with impaired glucose tolerance or recently diagnosed T2DM, worsening of blood glucose in adolescents is more common and is mainly related to lower baseline β-cell response

references:

Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study.